Therapy with CpG ODN and MoAb enhances survival as effectively as therapy with IL-2 and MoAb. Immunocompetent C3H mice were inoculated with 2,500 tumor cells IP on day 0. Therapy consisted of MoAb alone, CpG ODN alone, IL-2 alone, IL-2 and MoAb, or CpG ODN and MoAb. IL-2 (50,000 U) was administered IP twice daily on days 2, 3, and 4. CpG ODN (300 μg) was administered IP on day 2, and MoAb (50 μg) was administered on day 3 as in Fig 3. Each group contained 10 mice. Curves depict the percentage of survival over 60 days. No mice living at day 60 developed tumor, and all survived more than 5 months. No toxicity was observed in any group. (▪) No therapy; (•) MoAb on day 3; (▴) CpG ODN on day 2; (♦) IL-2 on days 2, 3, and 4; (⋄) IL-2 on days 2, 3, and 4 and MoAb on day 3; (○) CpG ODN on day 2 and MoAb on day 3.